SAGE Therapeutics Inc (SAGE) Stake Increased by Tocqueville Asset Management L.P.

Share on StockTwits

Tocqueville Asset Management L.P. grew its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 72.6% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 97,295 shares of the biopharmaceutical company’s stock after acquiring an additional 40,940 shares during the quarter. Tocqueville Asset Management L.P. owned about 0.21% of SAGE Therapeutics worth $15,230,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Flinton Capital Management LLC grew its stake in SAGE Therapeutics by 1,900.0% during the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 646 shares during the period. OppenheimerFunds Inc. grew its stake in SAGE Therapeutics by 2.2% during the second quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock worth $250,162,000 after purchasing an additional 34,389 shares during the period. DAFNA Capital Management LLC grew its stake in SAGE Therapeutics by 2.1% during the second quarter. DAFNA Capital Management LLC now owns 96,000 shares of the biopharmaceutical company’s stock worth $15,027,000 after purchasing an additional 2,000 shares during the period. Envestnet Asset Management Inc. grew its stake in SAGE Therapeutics by 149.6% during the second quarter. Envestnet Asset Management Inc. now owns 6,197 shares of the biopharmaceutical company’s stock worth $970,000 after purchasing an additional 3,714 shares during the period. Finally, FMR LLC grew its stake in SAGE Therapeutics by 1.6% in the second quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock valued at $1,092,169,000 after acquiring an additional 110,687 shares during the period.

SAGE stock opened at $163.49 on Friday. SAGE Therapeutics Inc has a twelve month low of $59.57 and a twelve month high of $195.97. The company has a market capitalization of $7.64 billion, a PE ratio of -23.06 and a beta of 2.90.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million during the quarter. sell-side analysts forecast that SAGE Therapeutics Inc will post -7.37 EPS for the current fiscal year.

A number of brokerages have commented on SAGE. BidaskClub raised SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Piper Jaffray Companies began coverage on SAGE Therapeutics in a research note on Monday, August 6th. They issued an “overweight” rating and a $206.00 price objective for the company. Cowen reissued a “buy” rating and issued a $207.00 price objective on shares of SAGE Therapeutics in a research note on Thursday, June 14th. Canaccord Genuity reissued a “buy” rating and issued a $220.00 price objective on shares of SAGE Therapeutics in a research note on Tuesday, June 12th. Finally, Morgan Stanley raised their price objective on SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Two analysts have rated the stock with a sell rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. SAGE Therapeutics has an average rating of “Buy” and an average target price of $199.19.

SAGE Therapeutics Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply